drugset
drugset / Trial / NCT00694122

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

NCT00694122 ↗

Phase 3 Completed 27 enrolled Massachusetts General Hospital Sanofi · collab
Non-randomizedCrossoverOpen-labelTreatment

Summary

1. To investigate the effect of insulin glargine (Lantus™) vs NPH insulin regarding glycemic control during the early AM (dawn phenomenon) in individuals with type 1 diabetes. 2. To measure hormones implicated in the pathogenesis of the dawn phenomenon in individuals with type 1 diabetes.

Timeline

Start
2005-06
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator insulin glargine Protein / enzyme biologic 20.2 iu Subcutaneous

Indications

type 1 diabetes mellitus